Monoclonal antibody-based immunotherapy is now considered to be a main component of
cancer therapy, alongside surgery, radiation, and chemotherapy. Monoclonal antibodies …

Immuno-oncology approaches have entered clinical practice, with tremendous progress
particularly in the field of T cell-engaging therapies over the past decade. Herein, we provide …

Resolving conflict of interest The Joint Task Force on Practice Parameters (JTFPP) is
committed to ensuring that all guidelines are based on the best scientific evidence at the …

In the last decade, a better understanding of the molecular pathogenesis of B-cell non-
Hodgkin lymphomas has resulted in the development of novel targeted therapies, such as …

Cancer Chemotherapy - Abstract - Europe PMC Sign in | Create an account https://orcid.org
Europe PMC Menu About Tools Developers Help Contact us Helpdesk Feedback Twitter Blog …

PURPOSE Patients with indolent non-Hodgkin lymphoma typically respond well to first-line
immunochemotherapy. At relapse, single-agent rituximab is commonly administered. Data …

Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established
efficacy, and a favorable and well-defined safety profile in patients with various CD20 …

In recent decades, immune checkpoint blockade and chimeric antigen receptor T cell (CAR-
T) therapy are two milestone achievements in clinical immunotherapy. However, both show …

Rituximab is a chimeric mouse/human monoclonal antibody (mAb) therapy with binding
specificity to CD20. It was the first therapeutic antibody approved for oncology patients and …

Background Copanlisib, an intravenous pan-class I PI3K inhibitor, showed efficacy and
safety as monotherapy in patients with relapsed or refractory indolent non-Hodgkin …